Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
Fundamentals
Mkt Cap
$286.11M
Volume
-
52W High
$15.74
52W Low
$2.83
PE Ratio
-3.11
Avg. Volume
1.43M
EPS (Annual)
-$1.18
P/B
0.93
Rev/Employee
$0.00
Earnings
Oct 29
54
Neutral Sentiment
How do you feel about FULC?
BKronic5
$FULC need an update since they want to make a deal for below everyone’s average cost on this piece of garbage company. Was looking promising on sickle cell then the awful news on 6/2